多奈哌齐和美金刚联合治疗阿尔茨海默病的临床疗效Meta分析  

Meta-analyses of Clinical Efficacy of Donepezil and Memantine inthe Treatment of Alzheimer’s Disease

作　　者：徐小敏 张其梅[1] XU Xiao-min;ZHANG Qi-mei(Department of Neurology,Yichang Central People’s Hospital,First Clinical Medical College of Three Gorges University,Hubei Yichang 443000,China)

机构地区：[1]三峡大学第一临床医学院宜昌市中心人民医院神经内科

出　　处：《临床医药文献电子杂志》2019年第68期5-8,共4页Electronic Journal of Clinical Medical Literature

摘　　要：目的全面评估多奈哌齐和美金刚联合治疗阿尔茨海默病(Alzheimer’s disease,AD)的临床疗效。方法在中国知网(CNKI)、维普中文期刊数据库(VIP)及万方数据库等官网上检索,检索时间截至2018年8月31日,按纳入与排除相关标准选择符合条件的临床随机对照研究对象试验(RCT),由两位研究者独立进行文献质量评估,同时提取相关资料及数据,运用软件RevMan5.3对数据进行处理及分析。结果共计选出8个RCT,合计患者649名。Meta分析显示,多奈哌齐联合美金刚与单用多奈哌齐在简易智力状况检查量表(MMSE)、老年性痴呆评定量表的认知分量表(ADAS-Cog)、日常生活活动能力量表(ADL)评价总分上无明显差别,但联合治疗在神经精神问卷(NPI)评价总分更具优势。结论多奈哌齐和美金刚两药联合治疗AD,在促使患者精神行为及情感的恢复方面疗效优于单一使用多奈哌齐。Objective To comprehensively evaluate the clinical efficacy of donepezil and memantine in the treatment of Alzheimer's disease in China.Methods According to inclusion and exclusion criteria,the qualified clinical randomized controlled trials(RCTs)from January 1,2014 to August 31,2018 were searched in CNKI,VIP and Wanfang databases.Two reviewers independently evaluated the methodological quality and extracted the data and the relevant information.The software RevMan 5.3 was used to process and analyze the data.Results The total 8 RCTs were included.There were 649 patients.Meta-analyses showed that there was no significant difference between the group of donepezil combine memantine and the memantine group in the total scores of MMSE,ADASCog and ADL,but the combined therapy had more advantages in NPI.Conclusion The combination of donepezil and memantine in treating AD was superior to donepezil in promoting the recovery of patients'mental behavior and emotion.

关 键 词：多奈哌齐 美金刚 阿尔茨海默病 疗效分析 

分 类 号：R74[医药卫生—神经病学与精神病学]